← Back to Search

Coping Long-term with Active Suicide Program for Schizophrenia for Schizophrenia (CLASP-S Trial)

N/A
Waitlist Available
Led By Brandon Gaudiano, PhD
Research Sponsored by Butler Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

CLASP-S Trial Summary

This trial is testing a new program to help people with schizophrenia who have been recently hospitalized for suicidal thoughts or behaviors. The program, called CLASP-S, is designed to help patients cope with suicidal thoughts and behaviors over the long term. The trial will compare the effects of CLASP-S to usual care on reducing suicidal thoughts and behaviors.

Eligible Conditions
  • Schizophrenia
  • Suicide

CLASP-S Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Client Satisfaction Questionnaire
Secondary outcome measures
Columbia Suicide Severity Rating Scale

CLASP-S Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Coping Long-term with Active Suicide Program for SchizophreniaExperimental Treatment2 Interventions
Coping Long-term with Active Suicide Program for Schizophrenia-Spectrum Disorders (CLASP-S) includes 3 individual sessions, 1 family meeting, and 11 phone sessions with the participant and their significant other over 6 months post-hospital discharge.
Group II: Enhanced Treatment as UsualActive Control1 Intervention
Participants assigned to Enhanced Treatment as Usual (ETAU) alone will receive unrestricted routine care in the community. Assessment feedback reports will be sent to participants' community providers at baseline, 3 months, and 6 months for care coordination.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Coping Long-term with Active Suicide Program for Schizophrenia
2020
N/A
~30
Enhanced Treatment as Usual
2016
Completed Phase 4
~770

Find a Location

Who is running the clinical trial?

Butler HospitalLead Sponsor
129 Previous Clinical Trials
16,388 Total Patients Enrolled
2 Trials studying Schizophrenia
242 Patients Enrolled for Schizophrenia
American Foundation for Suicide PreventionOTHER
33 Previous Clinical Trials
9,745 Total Patients Enrolled
Brandon Gaudiano, PhDPrincipal InvestigatorButler Hospital
7 Previous Clinical Trials
483 Total Patients Enrolled
1 Trials studying Schizophrenia
180 Patients Enrolled for Schizophrenia

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders
2020. "Suicide Prevention Intervention for Schizophrenia-Spectrum Disorders". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04221269.
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top